Intellia Therapeutics, Inc. (NTLA)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Feb 13, 2025

$9.64

P/E Ratio

N/A

Market Cap

$981.82M

Description
Add to research

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Metrics
Add to research

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerNTLA
  • Price$9.64+1.37%

Trading Information

  • Market cap$981.82M
  • Float94.27%
  • Average Daily Volume (1m)2,743,382
  • Average Daily Volume (3m)2,773,462
  • EPS-$5.45

Company

  • Revenue$43.09M
  • Rev growth (1yr)-24.02%
  • Net income-$135.71M
  • Gross margin71.38%
  • EBITDA margin-1,560.33%
  • EBITDA-$142.16M
  • EV$1.52B
  • EV/Revenue35.26
  • P/EN/A
  • P/S22.60
  • P/B1.02
  • Debt/Equity10.56
Documents
Add to research